Literature DB >> 7492228

Increased prevalence of symptomatic macrovascular disease in systemic sclerosis.

D J Veale1, T A Collidge, J J Belch.   

Abstract

OBJECTIVES: To determine the prevalence of symptomatic macrovascular disease, as defined by the World Health Organisation questionnaire for intermittent claudication, in patients with systemic sclerosis (SSc), and to compare the prevalence in this population with a cross sectional population study group reported in the Edinburgh Artery Study (EAS).
METHODS: A group of 53 patients with a diagnosis of limited or diffuse systemic sclerosis were identified from our register. They were asked to complete the WHO questionnaire to establish the presence or absence of intermittent claudication. In addition, each patient's case notes were reviewed to establish the existence of definite peripheral vascular disease and to determine their risk factor profile.
RESULTS: Forty six patients responded to the questionnaire, giving a response rate of 87%. Intermittent claudication was found in 10 SSc patients (21.7%) according to the questionnaire (two with diffuse and eight with limited SSc), compared with a prevalence rate of 4.6% for claudication in the EAS. Three SSc patients experienced clinical events attributable to occlusion of a major artery proven on angiography. Four patients had hypertension, there were three current and four ex-smokers, and two had increased total cholesterol. None of these patients had diabetes.
CONCLUSIONS: This study demonstrated a greater prevalence of macrovascular disease in patients with SSc than had been found in a neighbouring population.

Entities:  

Mesh:

Year:  1995        PMID: 7492228      PMCID: PMC1010024          DOI: 10.1136/ard.54.10.853

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  16 in total

1.  The diagnosis of ischaemic heart pain and intermittent claudication in field surveys.

Authors:  G A ROSE
Journal:  Bull World Health Organ       Date:  1962       Impact factor: 9.408

2.  Vascular damage and factor-VIII-related antigen in the rheumatic diseases.

Authors:  J J Belch; A A Zoma; I M Richards; K McLaughlin; C D Forbes; R D Sturrock
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

Review 3.  Large vessel arterial thrombosis in systemic sclerosis associated with antiphospholipid antibodies.

Authors:  L S Shapiro
Journal:  J Rheumatol       Date:  1990-05       Impact factor: 4.666

4.  Systemic involvement and immunologic findings in patients presenting with Raynaud's phenomenon.

Authors:  C G Kallenberg; A A Wouda; T H The
Journal:  Am J Med       Date:  1980-11       Impact factor: 4.965

5.  Evidence for an abnormal peripherally mediated vascular response to temperature in Raynaud's phenomenon.

Authors:  D Walmsley; M J Goodfield
Journal:  Br J Rheumatol       Date:  1990-06

6.  Large vessel occlusive disease associated with CREST syndrome and scleroderma.

Authors:  P Youssef; H Englert; J Bertouch
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

7.  Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls.

Authors:  W A D'Angelo; J F Fries; A T Masi; L E Shulman
Journal:  Am J Med       Date:  1969-03       Impact factor: 4.965

Review 8.  Vascular disease in progressive systemic sclerosis (scleroderma).

Authors:  W L Norton; J M Nardo
Journal:  Ann Intern Med       Date:  1970-08       Impact factor: 25.391

9.  Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis.

Authors:  A Kahan; J Y Devaux; B Amor; C J Menkès; S Weber; A Nitenberg; A Venot; F Guérin; M Degeorges; J C Roucayrol
Journal:  N Engl J Med       Date:  1986-05-29       Impact factor: 91.245

10.  Hemiplegia and peripheral gangrene secondary to large and medium size vessels involvement in C.R.E.S.T. syndrome.

Authors:  J Merino; B Casanueva; E Piney; F Val Bernal; V Rodriguez-Valverde
Journal:  Clin Rheumatol       Date:  1982-12       Impact factor: 2.980

View more
  25 in total

1.  European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres.

Authors:  A Della Rossa; G Valentini; S Bombardieri; W Bencivelli; A J Silman; S D'Angelo; M M Cerinic; J F Belch; C M Black; R Becvar; P Bruhlman; F Cozzi; L Czirják; A A Drosos; B Dziankowska; C Ferri; A Gabrielli; R Giacomelli; G Hayem; M Inanc; N J McHugh; H Nielsen; R Scorza; E Tirri; F H van den Hoogen; P G Vlachoyiannopoulos
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

2.  The natural course of progressive systemic sclerosis patients with interstitial lung involvement.

Authors:  Musellim Benan; Ikitimur Hande; Ongen Gul
Journal:  Clin Rheumatol       Date:  2006-04-25       Impact factor: 2.980

3.  Serum lipid profile in patients with systemic sclerosis: relationship to the thyreometabolic state.

Authors:  P J Kotyla; J Gozdzik; M Lewicki; A T Kotulska; E J Kucharz
Journal:  Rheumatol Int       Date:  2005-11-12       Impact factor: 2.631

4.  Atherosclerosis in Systemic Sclerosis: a Modern Controversy.

Authors:  Stefania L Magda; Raluca I Mincu; Carmen M Mihai; Mircea Cinteza; Dragos Vinereanu
Journal:  Maedica (Buchar)       Date:  2015-09

5.  Neurosonological and cognitive screening for evaluation of systemic sclerosis patients.

Authors:  B R Sakr; R E Rabea; A M Aboulfotooh; N A Kishk
Journal:  Clin Rheumatol       Date:  2019-02-26       Impact factor: 2.980

6.  Raynaud's phenomenon.

Authors:  Ariane Herrick
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-04

7.  Evaluation of arterial stiffness and hemodynamics by oscillometric method in patients with systemic sclerosis.

Authors:  Murat Sunbul; Kursat Tigen; Gulsen Ozen; Erdal Durmus; Tarik Kivrak; Altug Cincin; Alper Kepez; Halil Atas; Haner Direskeneli; Yelda Basaran
Journal:  Wien Klin Wochenschr       Date:  2013-07-12       Impact factor: 1.704

8.  Macrovascular disease and systemic sclerosis.

Authors:  M Ho; D Veale; C Eastmond; G Nuki; J Belch
Journal:  Ann Rheum Dis       Date:  2000-01       Impact factor: 19.103

9.  Distribution of macrovascular disease in scleroderma.

Authors:  L Stafford; H Englert; J Gover; J Bertouch
Journal:  Ann Rheum Dis       Date:  1998-08       Impact factor: 19.103

10.  The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study.

Authors:  Ada Man; Yanyan Zhu; Yuqing Zhang; Maureen Dubreuil; Young Hee Rho; Christine Peloquin; Robert W Simms; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2012-08-17       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.